IRIS
CIMADAMORE, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.293
AS - Asia 3.907
EU - Europa 2.768
SA - Sud America 709
AF - Africa 301
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 1
Totale 18.987
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.179
SG - Singapore 1.572
RU - Federazione Russa 766
VN - Vietnam 696
CN - Cina 589
BR - Brasile 549
HK - Hong Kong 511
IE - Irlanda 434
IT - Italia 304
SE - Svezia 259
DE - Germania 242
FR - Francia 216
CI - Costa d'Avorio 191
GB - Regno Unito 178
IN - India 139
UA - Ucraina 119
BD - Bangladesh 72
FI - Finlandia 64
JP - Giappone 51
AR - Argentina 46
MX - Messico 45
CA - Canada 42
CO - Colombia 40
NL - Olanda 34
ZA - Sudafrica 34
PL - Polonia 31
IQ - Iraq 30
KR - Corea 28
TR - Turchia 27
ID - Indonesia 26
MA - Marocco 24
PH - Filippine 22
EC - Ecuador 21
PK - Pakistan 21
ES - Italia 20
BE - Belgio 19
UZ - Uzbekistan 18
VE - Venezuela 18
EE - Estonia 13
DK - Danimarca 12
MY - Malesia 12
CL - Cile 11
EG - Egitto 11
SA - Arabia Saudita 11
TN - Tunisia 11
TH - Thailandia 9
AU - Australia 8
BO - Bolivia 8
IL - Israele 8
JO - Giordania 8
KZ - Kazakistan 8
RO - Romania 7
AT - Austria 6
BG - Bulgaria 6
CZ - Repubblica Ceca 6
PY - Paraguay 6
UY - Uruguay 6
CR - Costa Rica 5
DO - Repubblica Dominicana 5
DZ - Algeria 5
KG - Kirghizistan 5
LB - Libano 5
NP - Nepal 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
ET - Etiopia 4
KE - Kenya 4
LT - Lituania 4
NI - Nicaragua 4
OM - Oman 4
AL - Albania 3
AO - Angola 3
BH - Bahrain 3
CH - Svizzera 3
GA - Gabon 3
HN - Honduras 3
LU - Lussemburgo 3
LY - Libia 3
PE - Perù 3
PS - Palestinian Territory 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
GD - Grenada 2
GE - Georgia 2
HR - Croazia 2
HU - Ungheria 2
IS - Islanda 2
KH - Cambogia 2
PA - Panama 2
RS - Serbia 2
SN - Senegal 2
ZW - Zimbabwe 2
AD - Andorra 1
BN - Brunei Darussalam 1
BT - Bhutan 1
BY - Bielorussia 1
CY - Cipro 1
Totale 18.970
Salva come PNG Salva come JPEG
Città #
Ashburn 1.629
Des Moines 1.473
Singapore 1.190
Chandler 1.178
Fairfield 666
Dallas 566
Hong Kong 498
San Jose 467
Dublin 425
Wilmington 347
Boardman 322
Woodbridge 282
Houston 257
Seattle 255
The Dalles 246
Ho Chi Minh City 224
Cambridge 214
Jacksonville 200
Abidjan 191
Lawrence 167
Princeton 167
New York 165
Lauterbourg 158
Hanoi 150
Los Angeles 146
Beijing 145
San Mateo 142
Ann Arbor 135
Moscow 128
Council Bluffs 106
San Diego 102
Munich 81
Washington 73
Redmond 72
Pune 65
São Paulo 54
Columbus 50
London 48
Chicago 45
Orem 45
Santa Clara 45
Tokyo 44
Hefei 39
Helsinki 39
Da Nang 36
Haiphong 36
Ancona 33
Falls Church 31
Buffalo 29
Shanghai 29
Wuhan 28
Warsaw 27
Frankfurt am Main 24
Guangzhou 24
Turku 24
Brooklyn 23
Manchester 23
Stockholm 22
Montreal 21
Rome 21
Brussels 19
Denver 19
Norwalk 19
Phoenix 19
Turin 19
Chennai 18
San Francisco 18
Amsterdam 17
Atlanta 17
Seoul 17
Dhaka 16
Mexico City 16
Tashkent 16
Jiaxing 15
Rio de Janeiro 15
Boston 13
Brasília 13
Can Tho 13
Johannesburg 12
Poplar 12
Baghdad 11
Curitiba 11
Jakarta 11
Medellín 11
Porto Alegre 11
Bogotá 10
Cape Town 10
Hải Dương 10
Prescot 10
Salt Lake City 10
Thái Nguyên 10
Elk Grove Village 9
Forlì 9
Istanbul 9
Milan 9
Toronto 9
Amman 8
Cairo 8
Caracas 8
Centro 8
Totale 13.987
Salva come PNG Salva come JPEG
Nome #
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 212
Immunotherapy in genitourinary cancers: Where are we going? 205
Designing novel immunocombinations in metastatic renal cell carcinoma 201
Are liver nested stromal epithelial tumors always low aggressive? 198
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 194
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 189
Predicting future cancer burden in the United States by artificial neural networks 186
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 176
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 176
Biomarkers of angiogenesis and clinical outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Randomized Phase III METEOR Trial 173
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 170
Exploring the Spectrum of Kidney Ciliopathies 163
The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors 163
Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets 160
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 158
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 158
An update on investigational therapies that target STAT3 for the treatment of cancer 154
Microbiome and cancers, with focus on genitourinary tumors 152
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer 150
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 149
Detection limits of significant prostate cancer using multiparametric MR and digital rectal examination in men with low serum PSA: Up-date of the Italian Society of Integrated Diagnostic in Urology 149
Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View 148
The role of obesity in renal cell carcinoma patients: Clinical-pathological implications 146
Bone targeting agents in patients with metastatic prostate cancer: State of the art 144
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 143
Molecular characterization of testicular germ cell tumors using tissue microdissection 142
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 141
Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review 140
Is There a Role for Immunotherapy in Prostate Cancer? 139
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 138
The 1996 European Urology Focus on Preneoplastic Lesions of the Prostate 137
Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians 135
Molecular diagnostics in uro-oncology 132
Pd-l1 inhibitors for the treatment of prostate cancer 132
Clinicopathologic analysis of upper urinary tract carcinoma with variant histology 131
Emerging prognostic biomarkers in testicular germ cell tumors: Looking beyond established practice 131
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 130
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers 129
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 128
Epigenetic modifications and modulators in prostate cancer 128
Inguinal bladder hernia with lipomatosis of the bladder wall: A potential clinical pitfall for cancer 128
Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule 128
Vascular Enlargement as a Predictor of Nodal Involvement in Bladder Cancer 127
Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View 127
Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype 126
The identification of immunological biomarkers in kidney cancers 126
From undergraduate medical school student to visible pathologist 125
Surgical pathology of cystic renal cell carcinomas: is there an overestimation of malignancy? 124
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? 124
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 124
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 123
RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications 123
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 123
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 122
The human microbiota and prostate cancer: Friend or foe? 122
p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading 122
Biphasic Tumors of the Urogenital Tract: Selected Topics 122
pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging 121
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 120
Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer 120
Genitourinary tumors: Update on molecular biomarkers for diagnosis, prognosis and prediction of response to therapy 120
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 120
Current application of the enhanced recovery after surgery protocol for patients undergoing radical cystectomy: lessons learned from European excellence centers 119
Immune checkpoint inhibitors for the treatment of bladder cancer 119
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial 119
Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice 118
An update on immunotherapy in uro-oncology 118
Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma 118
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer 117
Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion 117
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution 117
Pathology and molecular updates in tumors of the prostate: towards a personalized approach. 116
Grading of Chromophobe Renal Cell Carcinoma: Do We Need It? 116
Variants of Bladder Cancer: The Pathologist's Point of View 116
Circulating tumor dna testing for homology recombination repair genes in prostate cancer: From the lab to the clinic 116
Syndrome of inappropriate antidiuresis in prostate adenocarcinoma with neuroendocrine differentiation: a case report and literature review 115
Renal Cell Carcinoma: genomic landscape and clinical implications 115
Liquid biopsy in the clinical management of bladder cancer: current status and future developments 114
Prostate cancer grading in 2018: Limitations, implementations, cribriform morphology, and biological markers 114
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 111
Epigenetic modulations and lineage plasticity in advanced prostate cancer 111
Pathology without microscope: From a projection screen to a virtual slide 111
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? 110
Variants and new entities of bladder cancer 110
Treating prostate cancer by antibody-drug conjugates 110
PreImplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness 108
Agent-Based Learning Model for the Obesity Paradox in RCC 108
Molecular Pathology of Urothelial Carcinoma 108
Prostate cancer in 2021: Novelties in prognostic and therapeutic biomarker evaluation 108
Narrative review: Predicting future molecular and clinical profiles of prostate cancer in the United States 108
Exploring small extracellular vesicles for precision medicine in prostate cancer 107
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 107
Digital frozen section of the prostate surface during radical prostatectomy: a novel approach to evaluate surgical margins 106
Long Non-coding RNAs in prostate cancer with emphasis on second chromosome locus associated with prostate-1 expression 105
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay 105
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer 103
Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer 103
Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer 103
Emerging molecular technologies in renal cell carcinoma: Liquid biopsy 102
Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC 102
Totale 13.177
Salva come PNG Salva come JPEG
Categoria #
all - tutte 96.944
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 96.944
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021473 0 0 0 0 0 0 0 0 0 200 230 43
2021/20221.512 267 171 79 23 50 179 28 90 128 116 87 294
2022/20234.130 266 288 156 313 218 1.705 3 234 680 16 178 73
2023/20241.610 282 45 138 162 248 358 22 49 5 57 24 220
2024/20252.948 376 229 35 52 103 121 226 107 750 305 259 385
2025/20266.642 396 441 441 288 1.024 469 1.490 741 733 619 0 0
Totale 19.222